Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Non-Current Assets (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Non-Current Assets over the past 10 years, most recently at $4.7 million for Q4 2023.

  • For Q4 2023, Non-Current Assets fell 22.91% year-over-year to $4.7 million; the TTM value through Dec 2023 reached $21.0 million, down 21.05%, while the annual FY2023 figure was $4.7 million, 22.91% down from the prior year.
  • Non-Current Assets for Q4 2023 was $4.7 million at Corbus Pharmaceuticals Holdings, down from $5.1 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $11.0 million in Q4 2019 and troughed at $4.7 million in Q4 2023.
  • A 5-year average of $8.1 million and a median of $8.2 million in 2019 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 299.7% in 2019 and later fell 26.97% in 2022.
  • Year by year, Non-Current Assets stood at $11.0 million in 2019, then dropped by 6.99% to $10.2 million in 2020, then decreased by 26.37% to $7.5 million in 2021, then decreased by 18.53% to $6.1 million in 2022, then decreased by 22.91% to $4.7 million in 2023.
  • Business Quant data shows Non-Current Assets for CRBP at $4.7 million in Q4 2023, $5.1 million in Q3 2023, and $5.4 million in Q2 2023.